Led by Timothee Olivier, our new paper is now out at @JAMANetworkOpen
We analyze 12 years of FDA approvals, and do the hard work of sorting them into
New Mechanism of Action (MOA)
& New MOA for that tumor type
Vs next in class
jamanetwork.com/journals/jaman…
First we find, more drug approvals over time!
More approvals means more innovation, right?
Next we show how many drug approvals are truly innovative
The dark bar shows the first approval of a new MOA across tumor types, or within a tumor type (bottom pane)
(bottom pane) the brown bar is moving to an earlier line
light blue = next in class
The real measure of innovation 👇👇👇
The proportion of the approvals that are truly innovative
It has stagnated in recent years, and is a minority
Hundreds of new approvals, but only a few dozen new targets
Conclusion: we continue to suffer from a me-too mentality in oncology, as wisely shown by Fojo, 7 years ago
Most of our new drugs are duplicative MOA, or merely seek to claim larger market share for existing drugs
Often these trials have serious biases (misuse of Xover)
Cancer drug development should prioritize truly innovative and transformational approaches.
We may someday have 20 PD1 drugs, but we might do better to explore novel ways to fight the disease
Incentives structures need reconsideration.
jamanetwork.com/journals/jaman…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.